Objective-Traditional risk factors for coronary artery disease (CAD) fail to adequately distinguish patients who have atherosclerotic plaques susceptible to instability from those who have more benign forms. Using plasma lipid profiling, this study aimed to provide insight into disease pathogenesis and evaluate the potential of lipid profiles to assess risk of future plaque instability. Methods and Results-Plasma lipid profiles containing 305 lipids were measured on 220 individuals (matched healthy controls, nϭ80; stable angina, nϭ60; unstable coronary syndrome, nϭ80) using electrospray-ionisation tandem mass spectrometry. ReliefF feature selection coupled with an L2-regularized logistic regression based classifier was used to create multivariate classification models which were verified via 3-fold cross-validation (1000 repeats). Models incorporating both lipids and traditional risk factors provided improved classification of unstable CAD from stable CAD (C-statisticϭ0.875, 95% CI 0.874 -0.877) compared with models containing only traditional risk factors (C-statisticϭ0.796, 95% CI 0.795-0.798). Many of the lipids identified as discriminatory for unstable CAD displayed an association with disease acuity (severity), suggesting that they are antecedents to the onset of acute coronary syndrome. Conclusion-Plasma lipid profiling may contribute to a new approach to risk stratification for unstable CAD. (Arterioscler Thromb Vasc Biol. 2011;31:2723-2732.)
A cute coronary syndromes (unstable angina, myocardial infarction, and many cases of sudden cardiac death) are almost invariably the result of atherosclerotic plaque disruption and subsequent thrombosis (atherothrombosis). Although plaque accumulation and development is progressive throughout life, plaques may cycle between being stable and unstable throughout the disease process. Accurate identification of those at risk for unstable coronary syndromes is an important prerequisite to targeted treatment and prevention. However, current screening is limited by the predictive power of available tests, the high cost of these tests, or a combination of both. Furthermore, the ability of these tests to subclassify patients with CAD as having stable or unstable disease has been limited.
Risk assessment for coronary artery disease (CAD) is currently performed by the evaluation of traditional risk factors (eg, smoking status, body mass index, cholesterol level, blood pressure); by direct measures of arterial structural changes associated with atherosclerosis, such as carotid intima-medial thickness and the coronary artery calcification score; or by testing for myocardial ischemia using stress testing. For the most part, the addition of circulating biomarkers has added little to risk assessment by conventional methods, although the recent reports by Blankenberg et al 1 indicate that risk scores incorporating multiple biomarkers can improve on conventional risk models, and the report of Schnabel et al 2 suggests that this strategy may also be useful in the setting of stable CAD. The development of noninvasive screening tests that could predict plaque instability with a high degree of accuracy would be of tremendous significance and may have a major impact on how we manage this most prevalent of diseases.
Lipids play a key role in the formation and subsequent disruption of atherosclerotic plaques. From the formation of lipid-laden foam cells within the intima to the necrotic lipid core of unstable plaque, 3, 4 altered lipid metabolism and dyslipidemia associated with inflammation and oxidative stress are primary drivers of the pathological changes. Thus, although it has long been recognized that plasma cholesterol levels and low-density lipoprotein/high-density lipoprotein contribute to risk prediction models for coronary heart disease, it is now becoming clear that many other lipid types are important in atherogenesis. As such, these lipid species are potentially useful biomarkers for atherosclerosis and may be a basis for the prediction of acute coronary syndromes.
Methods

Participant Recruitment and Sample Collection
Written informed consent was obtained from all control and CAD participants, and the project approved by the Ethics Committee of the Alfred Hospital and conformed to the Declaration of Helsinki. A total of 140 patients with de novo presentation of CAD who were undergoing coronary angiography at the Alfred Hospital's cardiac catheterization laboratory were recruited between April 2003 and May 2005. 5 Patients who had undergone previous coronary revascularization were excluded. Patients were classified as either stable (nϭ60) or unstable (nϭ80) by 2 independent cardiologists on the basis of their symptoms, 12-lead ECG, and cardiac troponin I measurements in accordance with the Braunwald criteria. 5, 6 Plasma samples from a cohort of 80 healthy individuals were obtained from the AusDiab Biobank. 7 These individuals were recruited in 2000; were not receiving medication for high cholesterol, diabetes, or hypertension; had no history of myocardial infarction; and had a median 5-year Framingham risk of 7%. Venous blood samples were collected and plasma was prepared by centrifugation (1500g, 10 minutes, 4°C) within 24 hours of collection and stored at Ϫ80°C until required.
The rationale for the selection of a healthy comparison group was to examine the extreme ends of the clinical spectrum (healthy individuals and CAD patients) and thus enable identification of relevant lipids that could be evaluated for their capacity to differentiate stable CAD from unstable CAD.
Sample Preparation and Lipid Extraction
Plasma samples were randomized before lipid extraction and analysis. Plasma samples (200 L) were thawed and treated with the antioxidant butylhydroxytoluene (1 L of 100 mmol/L in ethanol). Total lipid extraction from a 10-L aliquot of plasma was performed by a single-phase chloroform:methanol (2:1) extraction (Supplemental Data, available online at http://atvb.ahajournals.org). 
High-Performance Liquid Chromatography-Mass Spectrometry Analysis
Lipid analysis was performed by liquid chromatography, electrospray ionization-tandem mass spectrometry using a Agilent 1200 liquid chromatography system combined with an Applied Biosystems API 4000 Q/TRAP mass spectrometer with a turbo-ionspray source (350°C) and Analyst 1.5 data system (Supplemental Data). Precursor ion scans and neutral loss scans were performed on plasma extracts from healthy individuals to identify the major lipid species of the following lipid groups: ceramide, monohexosylceramide, dihexosylceramide, trihexosylceramide, G M3 ganglioside, sphingomyelin, phosphatidylglycerol, phosphatidylinositol (PI), phosphatidylethanolamine (PE), lysophosphatidylethanolamine (LPE), alkylphosphatidylethanolamine (PE(O)), phosphatidylethanolamine plasmalogen (PE(P)), phosphatidylcholine, lysophosphatidylcholine (LPC), alkylphosphatidylcholine, phosphatidylcholine plasmalogen, lysoalkylphosphatidylcholine, cholesterol ester (CE), diacylglycerol (DG), and triaclyglycerol (Supplemental Table I ).
Multiple reaction monitoring experiments were established for each lipid species identified from the precursor ion and neutral loss scans ( Supplemental Table I ). A total of 63 DG and triaclyglycerol species and 242 other lipid species were analyzed in 2 separate experiments. These experiments were used to determine lipid profiles consisting of 305 lipid species on the total cohort (220 individuals) in addition to 38 quality control samples that were evenly spaced within the analytic run. Results were expressed as pmol/mL of plasma. Values for each lipid class were calculated as the sum of the individual lipid species.
Statistical Analysis
Knowledge of 1 or more traditional risk factors in 16 participants was missing, and these were determined from linear regression against the plasma lipids. Comparisons between variables in Tables  1 and 2 were by the 2 test for categorical variables, whereas continuous variables were compared by t test (normally distributed) or Mann-Whitney U test (nonnormally distributed). To determine the association of individual lipid species and lipid classes against different stages of disease, we performed binary logistic regression of lipid species against stable CAD versus control and unstable CAD versus stable CAD, adjusting for age, sex, body mass index (BMI), systolic blood pressure, fasting blood glucose, and statin use as appropriate. We acknowledge the need for multiple testing correction in performing repeated logistic regression to identify association of the predictor variable with outcome. The basis of this is to ensure that a prescribed family-wise error rate (␣) is retained in an analysis involving more than 1 comparison such as that performed in this scenario. However, we feel that the use of the Bonferroni correction here is too conservative and leads to an actual family-wise error rate that is far less than the prescribed level of ␣. This is because the variables being tested, ie, the lipids, are highly correlated within their defined classes, as well as between certain lipid classes. Therefore, to maintain the rate of false-positives without inflating the rate of false-negatives unnecessarily, we have chosen to use a threshold of 0.01 to determine significant association of lipids with the respective outcomes.
Classical statistical analysis requires sample size to be in excess of the number of independent variables. In the context of highthroughput screens such as ours, there is a possibility that this Table 3 Abbreviations are as defined in Table 4 . *Adjusted for age, sex, BMI, SBP, and fasting blood glucose. †Adjusted for age, sex, BMI, SBP, and statin use.
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requirement might not be met when sample sizes are small. To overcome this challenge, we have used techniques in statistical machine learning, namely feature selection, classification, and crossvalidation to identify features (lipids) that are strongly associated with outcome (unstable CAD/stable CAD) through the use of readily generalizable linear models. The use of feature selection algorithms in machine learning often significantly improves the performance of classification/predictive models through the inclusion of features with high discriminative power and the exclusion of features with low discriminative power where discriminative power is the ability of the feature (lipids) to differentiate between samples of distinct classes.
In developing a computational model to classify unstable CAD versus stable CAD, we have used ReliefF 8 in the feature selection stage on a correlation-minimized set of lipids coupled with a classification model based on L2-regularized logistic regression. 9 We refer the reader to the supplemental material for full details of our computational model.
To assess the performance of our models, we used 3-fold cross validation (1000 repeats) where the predictive performance of each model was assessed by the C-statistic and accuracy. The C-statistic is equivalently known as the area under the receiver operating characteristic curve (AUC). The AUC is equal to the probability that a classification model will rank a randomly chosen positive instance higher than a randomly chosen negative one. An AUC value of 0.5 indicates random predictive performance, and predictive performance improves as AUC approaches 1. Accuracy, conversely measures the percentage of test instances correctly classified by the classification model.
The relative contribution of plasma lipids, traditional risk factors, and the combination of both to class assignment (unstable CAD versus stable CAD) was determined by the frequency of inclusion in our multivariate modeling exercise.
Results
Patient Characteristics
The patients in the stable and unstable cohorts did not differ in conventional risk factors, with the exception of smoking status and high-sensitivity C-reactive protein ( Table 1 ). The control group was matched for age, sex, and BMI but did differ in other clinical and biochemical parameters, as would be expected between healthy controls and CAD patients under lipid-lowering and antihypertensive treatment ( Table  1) . Medication use was similar between the stable and unstable groups with the exception of statin and anticoagulant use ( Table 2 ).
Plasma Lipid Profiling
The 220 plasma samples were randomized together with 38 quality control samples and then analyzed for the 305 lipid species using 2 scheduled multiple reaction monitoring experiments. The average coefficient of variation (%CV) for the individual lipid species within the quality control samples was 10.3%, with 90% below 17.5% and 99% below 30.6%. Those lipids that had a CV greater than 20% (nϭ17) were primarily lipid species that were in low abundance (Ͻ200 pmol/mL); none of these were included in the top-ranked lipid analytes used in the multivariate models.
Binary logistic regression analysis of the total lipid classes (sum of individual species within each class) and the individual lipid species against unstable CAD (versus stable CAD) adjusting for age, sex, BMI, systolic blood pressure, and statin use identified 5 lipid classes (dihexosylceramide, PI, PE(O), PE(P), LPC) that were significantly (PϽ0.05) associated with unstable CAD (Table 3) ; however, there were 50 individual lipid species that were significantly (PϽ0.01) associated with unstable CAD (Table 4 and Supplemental  Table II ). Regression against stable CAD (versus control), adjusting for age, sex, BMI, systolic blood pressure, and fasting blood glucose, identified 13 lipid classes that were significantly (PϽ0.05) associated with stable CAD (Table 3) and 102 lipids that were significantly (PϽ0.01) associated with stable CAD (Table 4 and Supplemental Table II) .
We observed considerable variation in the odds ratio of individual lipid species within a given class, even where the class itself did not show a significant difference between groups. Shorter chain length CE species particularly CE 14:0, CE 16:1, and CE 16:2 showed a negative association to unstable CAD (versus stable CAD), whereas the longer chain length species, particularly CE 20:3 and CE 20:4, were positively associated with stable CAD (versus control) ( Figure 1 and Supplemental Table II ). We also observed a strong positive association of DG species containing 20:3 and 20:4 fatty acids, particularly DG 18:1/20:3 and DG 18:1/20:4, with stable CAD (versus control) and a small but significant negative association of species containing 14:0 with unstable CAD (versus stable CAD) ( Figure 1 and Supplemental Table II) . LPC species showed a strong negative association with both stable CAD (versus control) and unstable CAD (versus stable CAD) for most species with the exception of LPC 20:3, LPC 20:4 LPC 22:1 and LPC 22:6 which showed a positive association or trend with stable CAD. Nine of the 17 PI species showed a negative association with unstable CAD (versus stable CAD), whereas a number of these containing a 20:4 fatty acid (PI 36:4, PI 38:4, PI 40:4, PI 40:5) were positively associated with stable CAD (versus control) ( Figure 2 and Supplemental Table II) .
Most PE and LPE species showed a positive association with stable CAD (versus control) but no association with unstable CAD (versus stable CAD). In contrast, the PE(O) and PE(P) species showed negative associations or trends with both unstable CAD (versus stable CAD) and no association with stable CAD (versus control), with the exception of 2 species of PE(P) containing 20:4 fatty acid, which were positively associated with stable CAD (Figure 3 and Supplemental Table II ).
To examine the effect of statin use on the plasma lipids, we performed a subanalysis of the stable CAD group on statins (nϭ32) against the stable CAD group not on statins (nϭ28). Eleven species of lipid were significantly different between these 2 groups (PϽ0.01); of these, 3 were also included in the list of 103 lipids that were significantly different between stable CAD and control, whereas 2 were common with the 50 lipid species that were significantly different between unstable CAD and stable CAD ( Supplemental Table III ).
Multivariate Analysis
Logistic regression based classification models were created within a 3-fold cross-validation framework repeated 1000 times to assess the relative contribution of lipids and traditional risk factors (age, sex, family history, diabetes, smoking, BMI, systolic blood pressure, total cholesterol, highdensity lipoprotein, triglycerides, and high-sensitivity C-reactive protein) to the differentiation of unstable CAD from stable CAD.
The number of lipids in the dataset was reduced from 305 to 105 based on the strength of the correlations between individual lipids. The ReliefF feature selection algorithm was then applied to determine the order of incorporation of lipids and traditional risk factors into multivariate models of increasing feature size (eg, 1, 2, 3, 4, . . . 116). The models consisted of lipids alone, risk factors alone, or lipids with risk factors. Multiple cross-validation repeats enabled us to rank the lipids and traditional risk factors based on their recurrent incorporation in the models. The ranked lists (top 20 features in the 20 feature models) for the lipids only and combined lipids and traditional risk factor models are shown in Table 5 . The ranking of the traditional risk factors was based on the average percentage of incorporation into the models containing 3 features ( Table 5) .
The mean C-statistic and percentage accuracy were plotted against the number of features used to construct the model to illustrate the change in performance of the models over the use of an increasing number of features (Figure 4 ). Models using lipids alone to discriminate unstable CAD from stable CAD showed a rapid increase in the C-statistic with increasing number of lipids, reaching 0.802 (CI 0.800 -0.804) with only 20 lipids and increasing to a maximum of 0.808 (CI 0.806 -0.810) with 35 lipids in the model. In comparison, models created with the traditional risk factors alone achieved a maximum C-statistic of 0.796 (CI 0.794 -0.798) with all 11 risk factors including high-sensitivity C-reactive protein. The models containing a combination of lipids and risk factors performed best, achieving a C-statistic of 0.869 (CI 0.868 -0.871) with 20 features and increasing to a maximum of 0.875 (CI 0.874 -0.877) with 34 features. This model also had the highest accuracy of 78.0% compared with risk factors alone (70.2%) or lipids alone (73.3%, Figure 4 ).
Discussion
This study has identified differences in the plasma lipidome between unstable CAD and stable CAD and between stable CAD and healthy control individuals. Our results demonstrate that multivariate models using multiple lipid species can accurately classify unstable CAD from stable CAD patients (Figure 4) . Although models incorporating only lipids showed a marginal improvement in the C-statistic, there was a marked improvement in the percentage accuracy over models created using traditional risk factors, including highsensitivity C-reactive protein. Models using a combination of lipids and traditional risk factors performed significantly better in both AUC and percentage accuracy. These findings indicate that plasma lipid profiling may have diagnostic and prognostic potential for the identification of individuals at risk for unstable coronary syndromes. One of the most prominent differences in the plasma lipid profile between unstable CAD and stable CAD was the concentration of PE(O), where 10 of the 12 species showed a negative association with unstable CAD (PϽ0.01) such that the concentration was 40.2% lower in the unstable CAD group. A similar relationship was observed with the PE(P) species (Ϫ18.6%). These associations appear to relate to the plaque stability rather than plaque burden, as we observed no difference in the concentrations of PE(O) or PE(P) between the control group and the stable CAD group (Ϫ3.5% and 1.3%, respectively). This is in contrast to the elevated PE levels observed in stable CAD relative to the control group (ϩ27%), further elevated in unstable CAD (ϩ12%). Alkyl-phospholipids (PE(O) and alkylphosphatidylcholine), as well as alkenylphospholipids (PE(P) and phosphatidylcholine plasmalogen, the plasmalogens), are susceptible to oxidation, with their high proportion of polyunsaturated fatty acids and alkyl/alkenyl linked fatty acids and have been reported to be more susceptible to oxidation. 10, 11 The decreased concentration of these species may therefore relate to higher oxidative stress in the unstable CAD group and the action of reactive oxygen species on these lipids. However, in contrast to the PE(O) and PE(P) species, the alkylphosphatidylcholine and phosphatidylcholine plasmalogen species displayed a significant negative association with stable CAD relative to control (Ϫ14.4% and Ϫ19.1%, respectively) but no association with unstable CAD relative to stable CAD. These results suggest differential roles of alkyl/alkenyl species of phosphatidylcholine relative to PE in the onset and progression of CAD.
Total PI was 13.6% lower in the unstable CAD group relative to the stable CAD group, with 5 of the 17 species showing a significant negative association (PϽ0.01). This is in contrast to the positive association observed with stable CAD relative to control for some species (notably PI 36:4, PI 38:4, and PI 40:4). The relevance of these observations may lie in the fact that PI, via the action of phospholipase A2, is the primary source of arachidonic acid, which is required for the biosynthesis of the prostaglandins and other eicosanoids that are involved in the activation of monocytes and macrophages and associated with matrix metalloproteinase production, a hallmark of plaque instability. 5 Thus, we observed an increase in the concentration of PI species containing arachidonic acid associated with stable CAD and a subsequent decrease associated with unstable CAD, suggesting that production of arachidonic acid from PI may be contributing to plaque instability.
The positive association of CEs and DGs containing arachidonic acid (C20:4) and its precursor eicosatrienoic acid (C20:3) with stable CAD (versus control) (Figure 1 ) further supports a difference in n-6 fatty acid metabolism in CAD. In particular, DG 18:1/20:4 and DG 18:1/20:3 display a strong odds ratio and corresponding elevation in plasma concentration (ϩ48% and ϩ53%, respectively) relative to the control group. Further evidence for altered arachidonic acid metabolism can be seen in the LPC species, which, for the most part, show a negative association with both stable CAD (versus control) and unstable CAD (versus stable CAD). The exceptions are LPC 20:3 and LPC 20:4, as well as LPC 22:1 and LPC 22:6, which show positive associations or trends with stable CAD. We also observe the highest associations between PE species and stable CAD with the arachidonic acid containing species PE 38:4 (odds ratio 5.2, 36% increase), PE 40:4 (odds ratio 7.4, 50% increase), and PE(P) 20:0/20:4 (odds ratio 3.2, 33% increase) ( Figure 3 and Supplemental  Table II ).
Although the action of phospholipase A2 would be expected to lead to the generation of LPCs, which has previously been positively associated with inflammation and atherosclerosis, 12, 13 we observed lower levels of most LPC species but higher levels of LPE, particularly LPE 20:4 and LPE 22:6. Because polyunsaturated fatty acids are predominantly found in the sn2 position of phospholipids, the elevated LPE 20:4 and LPE 22:6 are unlikely to result from phospholipase A2 activity. More likely, they are the result of reactive oxygen species degradation of PE(P) species to eliminate the vinyl ether linkage leaving the sn1 LPE species, as described above. In contrast, LPC species containing saturated fatty acids (likely sn1 linked) show the strongest associations to CAD. The lower levels of these LPC in circulation may result from an increase in the catabolism of these species or to their more efficient removal from circu- lation into tissues, either in the form of modified lipoprotein or directly from albumin, which represents the major form of plasma LPC. 14 Here also our observations suggest a differential role of the phosphatidylcholine and PE species in CAD.
Limitations
The differential use of statins in the stable CAD and control cohorts and between unstable CAD and stable CAD is a potential confounding effect on our analysis. This was addressed in the analysis of unstable CAD against the stable CAD cohort by inclusion of statin use as a covariate in the logistic regression analysis. However, this is not possible in the analysis of stable CAD relative to the control group in which no individuals were on statins. Although it is well established that statin use is associated with a decrease in plasma levels of cholesterol-derived lipids, the subanalysis of the stable CAD group on statins against the stable CAD group not on statins showed significance in only 2 of 23 cholesterol species. This is presumably a result of the normalization of elevated cholesterol in the statin-treated group such that they matched the nonstatin-treated group. Notwithstanding this result, very few noncholesterol-derived lipid species showed a significant association with statin use, and in fact most of these were not significantly associated with stable CAD (versus control). We therefore conclude that statin use is not a significant confounder in this study. We recognize the inherent limitations of a cross-sectional study to develop predictive models and the inability to determine temporal relationships and causality. However, many of the lipids identified as discriminatory for stable CAD (versus control) displayed a further association with disease acuity (severity), suggesting that they are altered before the onset of acute coronary syndrome.
Summary and Conclusion
Despite our incomplete knowledge of the lipid metabolism associated with CAD, we were able to apply ReliefF feature selection in tandem with L2-regularized logistic regression classification to develop and cross-validate multivariate models that achieve superior discrimination of disease status. The lipids most often incorporated into the multivariate models (Table 5 ) showed a strong homology with the top-ranked lipids identified by logistic regression (Table 4 and Supplemental Table II ). The relative distribution of these lipids within the lipoprotein pools has been the subject of a number of lipidomic studies, 15, 16 and for the most part, the lipids described in this study are distributed throughout the lipoprotein subfractions (albeit with different distributions). The exception to this is the lysophospholipids, which appear to be almost totally associated with the high-density lipoprotein and lipoprotein free fraction. 15 However, the differences we have observed may represent specific changes to particular lipoprotein subpopulations leading to altered structural and functional properties. Further subfractionation studies are now required to define these relationships.
Our results demonstrate the potential of plasma lipid profiling for the identification of unstable CAD. Although it appears likely that many of the changes in plasma lipids precede the development of plaque instability, further prospective studies are now required to validate the predictive ability of this approach to the identification of the vulnerable patient. Multivariate models of increasing feature size (eg, 1, 2, 3, 4, . . . 116) that included either lipids alone, risk factors (age, sex, family history, diabetes, smoking, body mass index [BMI], systolic blood pressure, total cholesterol, high-density lipoprotein, triglycerides, and high-sensitivity C-reactive protein) alone or lipids with risk factors were created using the ReliefF feature selection algorithm to determine the order of feature incorporation. Models were based on L2-regularized logistic regression within a 3-fold cross-validation framework (repeated 1000 times). The mean C-statistic and percentage accuracy from each model are plotted against the number of variables (solid lines). The 95% CIs are shown by the broken lines.
